We found AML patients had higher DPYSL2 mRNA levels than normal samples in the public database GEPIA (Figure 2A), and had higher protein levels in AML cell lines and AML patients than healthy donors (Figure 2B). This evidence concerns the gene DPYSL2 and acute myeloid leukemia.